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Management of systemic lupus erythematosus 
during pregnancy: challenges and solutions
Caroline L Knight
Catherine Nelson-Piercy
Division of women’s Health, women’s 
Health Academic Centre, King’s 
College London and King’s Health 
Partners, St Thomas’ Hospital, 
London, UK
Abstract: Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease 
predominantly affecting women, particularly those of childbearing age. SLE provides chal-
lenges in the prepregnancy, antenatal, intrapartum, and postpartum periods for these women, 
and for the medical, obstetric, and midwifery teams who provide their care. As with many 
medical conditions in pregnancy, the best maternal and fetal–neonatal outcomes are obtained 
with a planned pregnancy and a cohesive multidisciplinary approach. Effective prepregnancy 
risk assessment and counseling includes exploration of factors for poor pregnancy outcome, 
discussion of risks, and appropriate planning for pregnancy, with consideration of discussion 
of relative contraindications to pregnancy. In pregnancy, early referral for hospital-coordinated 
care, involvement of obstetricians and rheumatologists (and other specialists as required), an 
individual management plan, regular reviews, and early recognition of flares and complications 
are all important. Women are at risk of lupus flares, worsening renal impairment, onset of or 
worsening hypertension, preeclampsia, and/or venous thromboembolism, and miscarriage, intra-
uterine growth restriction, preterm delivery, and/or neonatal lupus syndrome (congenital heart 
block or neonatal lupus erythematosus). A cesarean section may be required in certain obstetric 
contexts (such as urgent preterm delivery for maternal and/or fetal well-being), but vaginal birth 
should be the aim for the majority of women. Postnatally, an ongoing individual management 
plan remains important, with neonatal management where necessary and rheumatology follow-
up. This article explores the challenges at each stage of pregnancy, discusses the effect of SLE 
on pregnancy and vice versa, and reviews antirheumatic medications with the latest guidance 
about their use and safety in pregnancy. Such information is required to effectively and safely 
manage each stage of pregnancy in women with SLE.
Keywords: systemic lupus erythematosus, preconception counseling, medication, management 
of pregnancy, pregnancy complications, neonatal lupus
Introduction
Systemic lupus erythematosus (SLE) is a rare, multisystem, chronic autoimmune 
disease which can vary from mild to life-threatening.1 It can present with a variety 
of symptoms including rash, arthritis, anemia, thrombocytopenia, serositis, nephritis, 
seizures, and/or psychosis.2 It typically shows a waxing and waning clinical course, 
but some patients have continuous disease activity.3
The overall incidence (newly diagnosed cases) in the UK in 1999–2012 was 
4.9/100,000 person-years. The incidence of SLE in women is six times higher than 
in men in the UK (8.34 vs 1.44/100,000 person-years);1 in premenopausal adults, 
the female-to-male ratio is 15:1.4 There are also marked variations in incidence in 
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different ethnic groups. In the UK, the highest incidence is 
in Black Caribbean women (31.5/100,000 person-years), 
and the incidence in Black other (22.3/100,000) and Black 
African (13.8/100,000) women is also increased. The rates in 
Pakistani (10.0/100,000), Indian (9.9/100,000), and Chinese 
women (9.4/100,000) are lower with the lowest incidence in 
White women (6.7/100,000).1
The overall prevalence (proportion of cases within a popu-
lation) in the UK in 1999–2012 was 97/100,000. The rate was 
6.8 times higher in women (170/100,000). The prevalence 
was the highest in Black Caribbean patients (518/100,000) 
and the lowest in White patients (135/100,000).1 These 
are similar to the US: Black vs White 400/100,000 vs 
100/100,000; female-to-male ratio is 10–15:1.3
Patients with SLE have increased mortality due to lupus 
complications or infection in earlier adult life, and myocardial 
infarction or stroke in later adult life.5 The overall survival 
in patients diagnosed with SLE is 92% after 10 years;6 thus, 
with modern drug therapies and management, many women 
with SLE of childbearing age are now conceiving. SLE is 
the commonest autoimmune rheumatic disease encountered 
in pregnancy; knowledge of pregnancy management in such 
patients is thus important.
General principles
Complications during pregnancy may be maternal (lupus 
flares, worsening renal impairment, onset of or worsening 
hypertension, development of preeclampsia, or venous 
thromboembolism [VTE]) and/or fetal–neonatal (miscar-
riage, intrauterine growth restriction [IUGR], preterm deliv-
ery, neonatal lupus syndrome [NLS]).7
As with many medical conditions in pregnancy, the best 
maternal and fetal–neonatal outcomes are obtained with a 
cohesive multidisciplinary approach. For patients with SLE, 
the multidisciplinary team may include a rheumatologist 
(ideally familiar with pregnancy in patients with SLE), 
obstetrician, nephrologist, fetal cardiologist, fetal medi-
cine specialist, neonatologist, and/or specialist midwife. 
The woman’s care should include effective prepregnancy 
risk assessment and stratification followed by individually 
tailored prepregnancy counseling. When she conceives, 
she should book early for pregnancy care with rheumatol-
ogy and obstetric appointments in the first trimester and 
an individually tailored antenatal management plan. Early 
recognition and management of flares and complications 
(medical and/or obstetric) are important, with involve-
ment of practitioners experienced in managing pregnancy 
in patients with SLE. Following delivery, an individually 
tailored postnatal management plan is equally important, 
including neonatal management where necessary and rheu-
matology follow-up.
This article examines challenges in the prepregnancy, 
antenatal, intrapartum, and postpartum periods for women 
with SLE and the medical, obstetric, and midwifery teams 
who provide their care.
Prepregnancy challenge: stratifying 
individual patient risk
The prepregnancy consultation should gather detailed infor-
mation (Table 1) to deduce a woman’s individual risks related 
to pregnancy. This should include past and current SLE 
disease activity (including most recent flare and frequency), 
preexisting organ damage (particularly cardiac, lung, and/or 
renal), medication history, and a recent serological profile 
(anti-dsDNA, anti-Ro/La antibodies, antiphospholipid anti-
bodies [aPL], complement). The presence of any additional 
medical disorders should be elicited, in particular hyperten-
sion, diabetes, renal disease, and VTE, along with any addi-
tional medications. The past obstetric history should include 
gestation and outcome of all pregnancies, with particular 
reference to fetal and/or neonatal losses or complications 
(miscarriage, stillbirth, small-for-gestational age [SGA], 
preterm birth, congenital heart block [CHB], and/or the 
rash of neonatal lupus erythematosus [NLE]) and maternal 
complications (preeclampsia, antenatal or postpartum flares, 
VTE). Baseline blood pressure and urinalysis should be 
performed in clinic. Baseline blood tests (full blood count 
[FBC], urea and electrolytes [U&E], creatinine, liver function 
tests [LFTs]) and serological profile, if not recently available, 
should be requested.8 Additional organ-specific tests (cardiac 
echo, lung function tests) may be helpful in assessing function 
in affected individuals.
Based on this information, women with SLE can be strati-
fied into the following groups: 1) current remission, or stable 
low disease activity, with stable treatment; 2) early-stage or 
Table 1 Prepregnancy consultation: information gathering
Past and current disease activity
Preexisting organ damage
Serological profile
Medication history
Additional medical disorders
Past obstetric history
Baseline blood pressure, urinalysis
FBC, U&e, creatinine, LFTs ± organ-specific investigations
Note: Data from Ateka-Barrutia et al.8
Abbreviations: FBC, full blood count; U&e, urea and electrolytes; LFTs, liver 
function tests.
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currently active disease; or 3) severe impairment of organ 
function ± preexisting severe organ damage.9
Women in group 3 are at particularly high risk of com-
plications including worsening disease progression and 
end-organ failure, and there will be serious pregnancy risks 
for both woman and fetus. Some clinical scenarios may be 
considered as relative or absolute contraindications to preg-
nancy (Table 2): these include moderate-to-severe lupus flare 
(including renal flare) or stroke within the past 6 months, 
pulmonary hypertension (estimated systolic pulmonary 
artery pressure >50 mmHg, or symptomatic), moderate-
to-severe heart failure (left ventricular ejection fraction 
<40%), severe valvulopathy, severe restrictive lung disease 
(forced vital capacity <50% predicted or <1 L), chronic kid-
ney disease (CKD) stage 4–5 (creatinine >2.5–2.8 mg/dL, 
>220–250 mmol/L; estimated glomerular filtration rate 
[GFR] <30 mL/min), or uncontrolled hypertension.7,8,10,11 
Women with previous severe early-onset preeclampsia 
(<28 weeks) or HELLP syndrome (a form of severe pre-
eclampsia: hemolysis, elevated liver enzymes, and low 
platelet count)12,13 despite therapy with aspirin plus heparin 
must also be considered an extremely high-risk group.7,8,10,11
Prepregnancy challenge: 
appropriate counseling
Stratification of women into these three groups enables an 
overall approach to management, with adjustment(s) for 
individual situations:8,9
1. SLE in remission, or stable low disease activity: medica-
tion should be reviewed and adjusted as necessary; those 
women should be advised that it is safe to plan a pregnancy.
2. SLE at an early stage following recent diagnosis, or active 
disease: those women should be encouraged to postpone 
pregnancy and use effective contraception; medication 
should be reviewed with prescription of immunosup-
pressives (ideally hydroxychloroquine [HCQ] and/or 
 azathioprine which will be safe in pregnancy); further 
review(s) should be done to monitor progress; once 
SLE condition improves (or ideally, enters remission), 
the women should be advised that it is safe to plan a 
pregnancy.
3. Severe impairment of organ function and/or preexisting 
severe organ damage (Table 2): those women should be 
advised about the serious risks to health and pregnancy-
related risks; pregnancy should be discouraged; alterna-
tives, including adoption and surrogacy (own or donor 
eggs), should be discussed.
Once the women are stable with inactive disease, discus-
sion of potential medical and obstetric risks, and appropriate 
planning for pregnancy, can be undertaken. Women should 
be reassured that while pregnancy with SLE is generally 
considered a high-risk pregnancy, a tailored management 
approach with close multidisciplinary surveillance in preg-
nancy and the puerperium will result in high rates of suc-
cessful pregnancies.8
For a woman with SLE, the medical risks are the possible 
effect(s) of pregnancy upon her SLE (flares, progressive 
organ damage). The obstetric risks are due to the effects of 
SLE upon her pregnancy for her (preeclampsia, VTE) and 
the fetus (miscarriage, IUGR, preterm birth, stillbirth, NLS); 
any previous obstetric history will also suggest the likelihood 
of complications in future pregnancies.
Women with active disease (current, or during 6 months 
prior to conception), lupus nephritis, or cardiac/lung involve-
ment are at higher risk of flares, and medical and/or obstetric 
complications during their pregnancy. Women with throm-
botic and/or obstetric antiphospholipid syndrome (APS) 
are at an increased risk of VTE and/or pregnancy loss, and 
may require aspirin and/or low-molecular weight heparin 
(LMWH) during pregnancy. Women with anti-Ro and/or 
anti-La antibodies should be counseled about the risks of 
fetal–neonatal CHB and/or NLE (Table 3).9,14,15
It is important to distinguish between aPL and APS. The 
international consensus statement on APS classification 
includes laboratory and clinical criteria. A diagnosis of aPL 
Table 2 Relative contraindications to pregnancy
Severe lupus flare (including renal flare) within the past 6 months
Stroke within the past 6 months
Pulmonary hypertension
Moderate-to-severe heart failure
Severe valvulopathy
Severe restrictive lung disease
Chronic kidney disease stage 4–5
Uncontrolled hypertension
Previous severe early-onset (<28 weeks) preeclampsia or HELLP 
  syndrome despite therapy with aspirin plus heparin
Note: Data from7,8,10,11.
Abbreviation: HeLLP Haemolysis, elevated Liver enzymes, Low Platelet count.
Table 3 Factors affecting pregnancy outcomes in SLe
Disease activity
Lupus nephritis (both in terms of hypertension and renal impairment)
Anti-Ro/anti-La antibodies
Antiphospholipid syndrome
Cardiac/lung involvement
Note: Data from9,14,15.
Abbreviation: SLe, systemic lupus erythematosus.
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requires two positive tests, >12 weeks apart, of at least one of 
lupus anticoagulant, anticardiolipin antibody (medium/high 
titer), and anti-beta2-glycoprotein I antibody.16 aPL may be 
present in up to 40% of patients with SLE, and 8%–10% of 
the normal population.17
APS is diagnosed if there are aPL with additional clinical 
features of thrombotic or obstetric complications. Throm-
botic APS involves one or more clinical episodes of arterial, 
venous, or small-vessel thrombosis. Obstetric APS involves 
the following: one or more adverse pregnancy outcomes 
(unexplained fetal death(s) ≥10 weeks of gestation; prema-
ture birth(s) of a morphologically normal fetus <34 weeks 
due to preeclampsia, eclampsia, or placental insufficiency 
(including birthweight less than tenth centile); or three or 
more unexplained consecutive spontaneous miscarriages 
<10 weeks).16
Soh et al compared pregnancy outcomes between women 
with aPL and obstetric APS. Both groups received aspirin in 
pregnancy; women with obstetric APS also received LMWH 
if they were at high risk of VTE, had previous late pregnancy 
complications, or previous adverse outcome(s) despite aspirin 
use. Women with aPL had similar obstetric outcomes to con-
trols, whereas those with obstetric APS had a fourfold higher 
rate of pregnancy-induced hypertension or preeclampsia and 
a fivefold higher rate of pregnancy loss, with significantly 
lower birthweight and increased rate of SGA. They thus 
recommend that women who only have aPL should receive 
aspirin, but not routine LMWH solely for aPL, and can be 
reassured and managed as those with normal pregnancy.17
aPL should also be considered in its context as risk factor 
for thromboembolism. If there are three other risk factors, 
the woman may be considered for antenatal LMWH; if there 
are two other risk factors, LMWH may be considered from 
28 weeks; if there is one other risk factor, postnatal LMWH 
may be considered for 10 days. Any woman receiving ante-
natal LMWH should continue this for 6 weeks postpartum.18
Women with thrombotic APS (who will often be on 
long-term oral anticoagulation) should be offered throm-
boprophylaxis with higher dose LMWH antenatally and for 
6 weeks postpartum, or until returned to oral anticoagulant 
therapy after delivery.19 During pregnancy, these women 
should be managed in collaboration with a hematologist and/
or rheumatologist with expertise in this area.18
Women with obstetric APS with recurrent miscarriage 
<10 weeks should take aspirin from preconception. If they 
have previously miscarried while taking aspirin, LMWH 
should be added from the confirmation of pregnancy. Consid-
eration may be given to discontinuing this either at 12 weeks 
or at 20 weeks if uterine artery waveform is normal at the 
anomaly scan.19
Women with obstetric APS with miscarriage ≥10 weeks 
of gestation or with premature birth(s) of a morphologically 
normal fetus <34 weeks due to preeclampsia, eclampsia, 
or placental insufficiency (including birthweight less than 
tenth centile) should take aspirin from preconception with 
LMWH added from confirmation of pregnancy. This should 
be continued antenatally and for 6 weeks postpartum.19
Other risk factors have been identified for pregnancies 
in women with SLE; in many cases, these relate to the fac-
tors listed in Table 3, predominantly complications from 
lupus nephritis. They include clinical factors (hyperten-
sion, nonreversible organ damage particularly CKD) and 
biochemical factors (hypocomplementemia, proteinuria 
>500 mg/24 hours, thrombocytopenia, GFR <60 mL/min/ 
1.73 m2, raised creatinine particularly >2.5–2.8 mg/dL and 
≥220–250 mmol/L).8,10,20–24
In addition to changing or stopping medication that could 
be harmful in pregnancy, and starting additional medication 
such as antihypertensives, all women with SLE should be 
advised to take low-dose aspirin (75 mg) from 12 weeks 
and throughout pregnancy to reduce their risk of developing 
preeclampsia.12,25
Appropriate vitamins and minerals should also be 
prescribed. Any woman planning to conceive should take 
400 mg folic acid daily to reduce the risk of fetal neural tube 
defects, ideally for 3 months preconception and the first 
3 months of pregnancy.25 If she has had methotrexate in the 
previous 3 months,10 and diabetes, obesity, or any history (or 
family history) of of neural tube defects, then she should be 
prescribed high-dose (5 mg) folic acid.27 All women should 
also take 10 mg vitamin D daily for bone and teeth health 
and development. Women at increased risk of vitamin D 
deficiency should have levels checked as they may require a 
higher dose.26 Calcium therapy is also recommended. Previ-
ously, this was for women on long-term corticosteroids or 
LMWH, or at high risk of osteoporosis. However, a recent 
meta-analysis of 13 randomized trials involving >15,000 
women showed that at least 1 g of calcium daily in pregnancy 
(vs placebo) resulted in >50% reduction in the risk of pre-
eclampsia, and 25% reduction in the risk of preterm delivery. 
As women with SLE are at an increased risk of preeclampsia, 
we recommend calcium supplementation for all.28
Finally, general preconception advise should be given. 
Smoking cessation should be recommended, with referral 
to a smoking cessation program. Alcohol intake should 
be reduced or stopped; recreational drugs should also be 
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stopped. These measures will improve her health, her chance 
of conceiving, and the health of her fetus. If a woman is 
overweight, she should be counseled about the importance 
of weight loss, ideally to normal body mass index (BMI) 
range (17.5–24.9 kg/m2) as this will also improve her chance 
of conceiving, and reduce her risk of miscarriage and other 
pregnancy complications (including gestational diabetes and 
VTE). Rubella immunity should be checked, and vaccina-
tion with measles, mumps, and rubella vaccine should be 
offered to nonimmune women (ensuring that they are not 
currently pregnant, and advising avoidance of pregnancy for 
a month). Hemoglobinopathy assessment may be undertaken 
in women at risk of being carriers of sickle cell disease or 
thalassemia.8,10
Fertility is generally not affected in patients with SLE, 
other than those with amenorrhea secondary to severe flares, 
CKD 3–5 (estimated GFR <60 mL/min), or ovarian failure 
following cyclophosphamide.11 Women with SLE who have 
not conceived spontaneously and wish to undergo assisted 
reproduction techniques, including in vitro fertilization, 
should be counseled about the increased risk of disease flare 
and VTE (especially women with ovarian hyperstimulation 
syndrome and/or other prothrombotic risk factors). Identifica-
tion of high-risk patients (Table 3), precycle counseling, and 
adequate thromboprophylaxis and surveillance are manda-
tory. In patients with APS, safer approaches may include 
ovarian stimulation with clomiphene, single embryo transfer, 
ongoing therapy (appropriate for pregnancy) to avoid disease 
flare, avoidance of ovarian hyperstimulation syndrome, and 
use of natural estradiol and/or progestogens administered 
vaginally.11
For women who are advised to delay pregnancy, appro-
priate and reliable methods of contraception should be dis-
cussed. One study of 212 women at a lupus center showed 
that 46% had faced some risks of unintended pregnancy, with 
23% having unprotected sex “most of the time”.29
Prepregnancy challenge: 
appropriate medication
The use of medication in pregnancy is often treated with 
understandable caution by manufacturers and medication 
administrative bodies, and is usually based on data from retro-
spective case series, isolated case reports, and animal studies.
The European League Against Rheumatism task force 
recently reviewed the use of antirheumatic drugs before and 
during pregnancy, and during lactation, including registry 
data and a systematic review of the literature. In 2016, they 
produced four overarching principles, as well as statements 
(“points to consider”), on the use of these drugs during preg-
nancy and lactation.30 The EULAR overarching principles 
include the importance of family planning, the aim to prevent 
or suppress disease activity in the mother whilst minimizing 
harm to the fetus/child, the balancing of risks of medication 
against risks of untreated disease, and the importance of 
multidisciplinary input (rheumatologist, obstetrician, patient) 
when making decisions about treatment.30 The British Soci-
ety for Rheumatology and British Health Professionals in 
Rheumatology also produced evidence-based guidelines in 
2016 on prescribing drugs in pregnancy and breastfeeding.31,32
Details of medications and safety information are 
provided in Table 4: anti-inflammatories and analgesics, 
corticosteroids (non-fluorinated), and immunosuppressants 
(including anti-malarials).8,9,31–35
Medications which are safe throughout pregnancy (all 
trimesters) and during lactation to maintain remission and/
or treat flare are HCQ, azathioprine, cyclosporine, and 
tacrolimus.9,30 The aim should be to use steroid-sparing 
immunosuppressants (such as azathioprine) with ideally no 
steroids or else the lowest effective maintenance dose (ideally 
<7.5 mg prednisolone per day).9,30 Corticosteroids are safe 
to control active disease symptoms; aspirin and paracetamol 
are also safe.9,30 Methotrexate, mycophenolate mofetil, and 
cyclophosphamide must be discontinued before pregnancy 
due to proven teratogenicity, and should not be used during 
lactation.30
In general, mild flares during pregnancy can be treated 
with HCQ and/or low-dose oral steroids (also possibly with 
nonsteroidal anti-inflammatory drugs if first or second trimes-
ter and previously responsive). Moderate or severe disease 
may require the use of pulsed intravenous methylprednisolone 
or high-dose oral steroids, followed by rapid reduction to 
low-dose maintenance oral steroids in combination with safe 
immunosuppressants. Intravenous immunoglobulin (IVIg) 
may also be necessary.
More severe cases may require a risk/benefit assessment 
and prioritization of maternal welfare over fetal concerns, 
with use of stronger agents such as mycophenolate mofetil 
or cyclophosphamide, and consideration of preterm delivery. 
Management of lupus nephritis flares during pregnancy may 
include pulsed steroid followed by a combination of pred-
nisolone, HCQ, azathioprine, or tacrolimus.
Antihypertensive medication for preexisting or preg-
nancy-induced hypertension/preeclampsia may include labet-
alol, methyldopa, and/or nifedipine as safe first-line treatment 
(singly or in combination) at any stage of conception, 
pregnancy, or lactation.12,19 Second-line treatments during 
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Management of systemic lupus erythematosus during pregnancy
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pregnancy include hydralazine or doxazosin.19 Angiotensin-
converting enzyme (ACE) inhibitors and/or angiotensin II 
receptor blockers should be stopped preconception as they 
are associated with an increased risk of congenital abnormali-
ties.12 Some women with renal disease who are planning to 
conceive may, after specialist input, continue ACE inhibitors 
until very early in pregnancy8 (eg, first positive pregnancy test 
after a missed menstrual period) and then switch to another 
(first-line) antihypertensive,32 as months without the renal 
protective effects of ACE inhibitors may be deleterious to 
their long-term health. ACE inhibitors (eg, enalapril) can be 
used safely postpartum, including during lactation.19
Antenatal challenge: maternal  
lupus flares
Pregnancy is considered a high-risk time in SLE patients, 
although studies provide conflicting results as to whether 
flares are more common or of unchanged frequency.44 The 
changes in hormonal profiles in pregnancy induce a shift 
from Th1 to Th2 lymphocyte dominance; thus, Th2-response 
autoimmune disorders, such as SLE, are more likely to flare.10
The LUMINA Study Group in the US looked at outcomes 
in SLE patients including assessment of cumulative and irre-
versible damage, irrespective of cause, in 12 organ systems. 
They found significant postpartum damage accrual. This was 
due to disease activity levels and the degree of damage prior 
to pregnancy, total disease duration, and pregnancy duration, 
rather than due to pregnancy per se. The strongest predictor of 
postpartum damage accrual was having more active disease 
prior to pregnancy.45
Overall, the risk of flare (antenatal or postpartum) appears 
to be dependent on disease activity 6–12 months prior to con-
ception. Women with quiescent SLE over this period have less 
risk of flare during pregnancy, whereas women with active 
SLE have a high risk of flare.10 Most flares are nonsevere7 
with articular, dermatological, and/or mild hematological 
involvement. These are usually well controlled with short-
term introduction or increase of oral steroids. Nonetheless, 
severe flares with major organ involvement may occur;10 the 
Hopkins Lupus Center in the US has suggested that renal, 
as well as hematological, flares may be more common in 
pregnancy.44
Lupus nephritis at conception confers a higher risk of 
flare during pregnancy, even in women in remission. One 
study of 113 pregnancies in 81 women with preexisting lupus 
nephritis showed a 30% flare rate during pregnancy or post-
partum;23 others suggest up to 60% likelihood.24 In women 
with previous lupus nephritis, pregnancy does not seem to 
endanger long-term renal function, although the higher the 
baseline creatinine, the greater the risk of deterioration.23 
Women with creatinine >2.5–2.8 mg/dL (>220–250 mmol/L) 
are most likely to suffer postpartum renal function decline.24
In addition to renal complications, women may also suffer 
from a worsening of hypertension, or onset of new hyperten-
sion and/or preeclampsia. The risk of VTE is also increased.
A recent systematic review established the protective 
effect of HCQ in terms of organ damage, flares, VTE, bone 
mass loss, and long-term survival in the general SLE popu-
lation, as well as the potential to prevent disease activity in 
pregnant women.46 Two prospective studies corroborated 
these findings, suggesting that women who had taken HCQ 
throughout pregnancy had lower disease activity scores and 
lower prednisolone doses at the end of pregnancy, whereas 
those who discontinued HCQ, or did not take it at all, had 
higher activity scores, more flares, and required higher doses 
of steroids.38,47 HCQ may also offer fetal benefits in women 
who have anti-Ro/La antibodies.39
Distinguishing pregnancy-associated signs and symptoms 
from those of SLE may be difficult. Involvement of, and 
assessment by, experienced physicians is important. Fatigue, 
mild arthralgia, hair loss, dyspnea, headaches, malar and 
palmar erythema, edema, anemia, and thrombocytopenia 
represent common ambiguous manifestations.7
Baseline bloods (FBC, U&E, creatinine, LFTs, sero-
logical profile) and urinalysis with proteinuria quantification 
should ideally be obtained prepregnancy and again in early 
pregnancy. These can help to monitor disease status and 
identify flares. In pregnancy, erythrocyte sedimentation rate 
is usually raised due to higher fibrinogen production in the 
liver;19,48 hence, it is not considered a valid marker of disease 
activity in pregnancy. Serum C3 and C4 levels also rise in 
pregnancy due to increased liver production,7 so they may 
remain within normal range even in women with active SLE. 
Relative variation, rather than absolute levels, of C3 and C4 
should be assessed. A fall of ≥25% in serum complement 
levels during pregnancy may suggest lupus flare.49
In patients with permanent significant protein loss due 
to previous lupus nephritis, proteinuria may increase dur-
ing pregnancy due to increased renal blood flow, without 
indicating active nephritis.7 This may be more pronounced 
in patients who stop ACE inhibitors and/or angiotensin II 
receptor blockers shortly before or early in pregnancy. Up 
to a doubling of proteinuria from the baseline level in early 
pregnancy is to be expected.10 Thromboprophylaxis with 
LMWH may be required if there is significant proteinuria; 
expert opinion suggests a threshold of protein:creatinine ratio 
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(PCR) >100–200 mg/mmol or 24-hour collection >1–2g/day 
during pregnancy.50,51
It can also be difficult to distinguish between infection and 
inflammation (flare) in patients with SLE (Table 5).8,52 This is 
important as sepsis is a prominent cause of indirect maternal 
mortality, as well as mortality in nonpregnant SLE patients. 
If there is any diagnostic doubt, it may be worth using IVIg 
for first-line treatment as this will dampen inflammation but 
not worsen infection (unlike high-dose steroids).8
Antenatal challenge: maternal 
obstetric complications
A 2008 study from the US involving >13,000 deliveries in 
women with a diagnosis of SLE showed that SLE patients 
have a 17- to 20-fold increased risk of maternal mortality 
(325/100,000 live births, or 0.32% risk in all SLE pregnan-
cies). However, it should be noted that while being higher 
than the background rate in uncomplicated pregnant women, 
this is actually several-fold lower than the annual mortality 
rate in nonpregnant SLE patients (0.8%–3.2%).20
Medical complications such as stroke, pulmonary embo-
lism (PE), deep vein thrombosis (DVT), major infections, 
bleeding, and thrombocytopenia are two to eight times more 
frequent among women with SLE.20
After controlling for confounding factors such as mater-
nal age, women with SLE still had higher risks of pulmonary 
hypertension, renal failure, and thrombophilia (thrombophilia 
predominantly due to APS) (odds ratio [OR] 2.6, 3.7, and 
20.9, respectively). The risk of major infections (sepsis, 
pneumonia) was also increased (OR 3.5–4.3). Hematologic 
complications including anemia, thrombocytopenia, and need 
for blood transfusion were increased (OR 12.6, 8.3, and 3.6, 
respectively), but the risks of antepartum and postpartum 
hemorrhage were less elevated (OR 1.8 and 1.2). The risk 
of thrombotic events (DVT, PE, and stroke: OR 7.9, 5.5, and 
6.5, respectively) was more than tenfold higher in women 
with SLE.20
It is important to note that while pregnancy can pose risks 
to a woman with SLE (which are certainly higher when com-
pared with a low-risk pregnant population), the risks may not 
be higher than in any other year of that woman’s life, given 
her underlying diagnosis of SLE.20
Conversely, those with SLE in remission without major 
organ involvement, or those with cutaneous lupus erythe-
matosus only, are likely to have a normal pregnancy with 
pregnancy outcomes comparable to those of the healthy 
population.7,10
The risk of preeclampsia is noticeably increased in 
women with SLE. Twenty-three percent or more may develop 
preeclampsia: two- to fourfold higher than the general popu-
lation.8,20,25 This risk may be even greater if they have had 
preeclampsia before (OR 7.19) or have APS (OR 9.72);53 
patients with lupus nephritis, chronic hypertension, and 
renal impairment and women on high-dose oral steroids are 
also at particular risk (the latter is likely to be reflective of 
disease activity, although steroids do increase blood pressure) 
after adjustment for maternal age.20,21,54 Other independent 
risk factors include hypertensive disease during a previous 
pregnancy, CKD, diabetes (type 1 or type 2), or two or more 
factors of first pregnancy, age ≥40 years, pregnancy interval 
≥10 years, BMI >35 kg/m2 at first visit, a family history of 
preeclampsia, or multiple pregnancy.12 Women with SLE 
also have a fourfold increased risk of developing eclampsia 
compared with the general population, although absolute 
numbers remain small (0.5% vs 0.09%).20
A meta-analysis showed a 10% risk reduction in pre-
eclampsia, preterm delivery <34 weeks, perinatal death, 
birthweight less than tenth centile, or serious pregnancy 
outcomes (maternal death, development of preeclampsia; 
preterm delivery, SGA fetus, stillbirth, or neonatal death) if 
women take aspirin from <16 weeks of gestation throughout 
pregnancy. This is thus recommended for all women with 
SLE in pregnancy.12,25
One particular challenge in pregnant patients with 
SLE is differentiating preeclampsia from lupus nephri-
tis (Table 6).7,8,24,55 This may be challenging as they have 
symptoms in common and may also coexist: women with 
preexisting renal disease are at higher risk of hypertensive 
complications during pregnancy, including preeclampsia.7,24
Table 5 Differentiating infection from inflammation (flare) in SLE 
patients
Features 
suggestive of 
infection
Features suggestive of 
inflammation (flare)
Features which 
may be common 
to both
Raised CRP Normal CRP (may be  
raised in pericarditis, 
pneumonitis, or arthritis)
Symptoms (nausea, 
vomiting, pleuritic 
pain, arthralgia)
Raised wCC Response to 
immunosuppression
Fever
Response to 
antibiotics
Low complement  
(C3 and C4)
Reduced wCC
Raised  
procalcitonin 
(intensive care 
setting)
Raised dsDNA antibodies
Note: Data from Ateka-Burrutia et al,8 and Beca et al.52
Abbreviations: SLe, systemic lupus erythematosus; CRP, C-reactive protein; 
wCC, white cell count.
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A renal biopsy may be indicated if the result would affect 
management, usually by confirming or refuting a diagnosis 
(and/or class) of lupus nephritis. Special care should be taken 
due to higher bleeding risks after biopsy in pregnancy.8
New biomarkers, including angiogenic factors such as pla-
cental growth factor, may help to diagnose preeclampsia13 and 
may be particularly important in the challenging situation of 
identifying superimposed preeclampsia in patients, including 
those with SLE and those who have underlying hypertension 
and/or renal disease. A recent study showed that, from 20 to 
42 weeks of gestation, lower maternal placental growth factor 
concentrations had high diagnostic accuracy for superimposed 
preeclampsia requiring delivery within 14 days.56
Antenatal challenge: fetal 
complications
The LUMINA Study Group in the US assessed the impact of 
SLE on pregnancy outcomes (n=102). Thirty-six percent of 
women with SLE had a good pregnancy outcome (37/102), 
and 64% had an adverse outcome (65/102). As a fraction of the 
whole group, approximately a fifth had miscarriage <20 weeks 
(n=21), termination of pregnancy (n=20), or preterm birth 
<34 weeks (n=19), with a tenth suffering stillbirth (n=5). It is, 
however, important to note that the reason for the termination 
(whether maternal request, or therapeutic for maternal and/or 
fetal indications) was not recorded. The authors also suggest 
that many patients in their study population may have lacked 
access to specialized obstetric–rheumatology care, which is 
known to have beneficial effects on pregnancy outcomes.21
A 2008 literature review suggested a comparable mean 
fetal death rate (miscarriage plus stillbirth) of 19.5% in women 
with SLE, although with a very wide range (4%–43%).57 
The rate was higher in patients with active SLE at concep-
tion (25%–52%);57 similarly high rates (53%) were seen in 
another cohort of lupus nephritis patients.58 Patients with 
inactive SLE at conception had much lower rates of fetal 
loss (8%–12%), comparable with healthy women.57 One 
paper reported a fourfold increase in the stillbirth rate in SLE 
patients, although this halved after excluding patients with 
CNS lupus.59 A recent American study of 83 pregnancies 
in women with SLE showed a pregnancy loss rate of 17%, 
comparable with the US average of 16.1%.60
Ongoing pregnancies in patients with SLE carry increased 
risks of SGA and/or IUGR (6%–35%).8,20,21 Monitoring fetal 
growth with ultrasound scans is thus important in any women 
with SLE with risk factors for poor pregnancy outcome 
(Table 3).
The rate of preterm labor and delivery (<37 weeks) is also 
increased to 21%–36% in pregnancies in women with SLE 
(higher in women with more active or complicated disease), 
compared with 12% national average.20,21,58,60 However, the 
figures for spontaneous labor, induced labor, and prelabor 
cesarean section within this preterm group were not available. 
In one study of pregnancies in SLE patients, mean pregnancy 
duration was 29.6 weeks.45 Renal involvement conveys a 
significant increase in the rate of lower mean birthweight 
babies and in preterm delivery compared with SLE patients 
without renal involvement.54,61
Antenatal/postnatal challenge: 
neonatal lupus
NLS is a rare complication affecting children born to moth-
ers with anti-Ro/La antibodies, found in 25%–40% (anti-
Ro) and 10%–15% (anti-La) women with SLE62 as well as 
other autoimmune diseases (eg, Sjögren’s syndrome). These 
IgG antibodies are actively transported across the placenta 
from 16 to 30 weeks of gestation.7 There are two main 
forms of NLS: NLE and CHB. Rarer forms include hepatic 
and  hematologic. Forms may coexist: for example, a child 
with CHB may also have skin manifestations. Cutaneous, 
hepatic, and hematologic symptoms are transient; CHB is 
permanent.63
Table 6 Differentiating lupus flare from preeclampsia
Features suggestive of preeclampsia Features suggestive of lupus flare Features that may be common 
to both
Severe headache Onset <20 weeks (more suggestive of SLE) Hypertension
Visual symptoms (including flashing lights) Active urinary sediment/cellular casts worsening proteinuria
epigastric or right upper quadrant tenderness Hematuria edema
Clonus (>2 beats) Low/falling complement levels Renal impairment
Abnormal LFTs High/increasing anti-dsDNA antibodies Thrombocytopenia
Rising uric acid level Evidence of flare involving other organs
Signs of hemolysis
Falling angiogenic factors (eg, PlGF, VEGF)
Note: Data from7,8,24,55.
Abbreviations: SLe, Systemic lupus erythematosus; LFTs, liver function tests; PlGF, placental growth factor; veGF, vascular endothelial growth factor.
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NLE occurs in 5% of children born to women with anti-
Ro/La antibodies. It generally presents within the first 2 weeks 
of life as erythematous geographical lesions in light-exposed 
areas, resembling those seen in subacute cutaneous lupus. 
The rash usually disappears within 6 months as the maternal 
antibodies are cleared, and does not leave residual scarring.63,64
The US Research Registry for Neonatal Lupus has 
assessed neonatal outcomes in 58 women with 77 pregnan-
cies following a child with NLE. Forty-nine percent of these 
pregnancies were affected with NLS, and 51% were unaf-
fected. Of the total 77 pregnancies, 30% (n=23) had NLE, 
18% (14) had CHB ± NLE, and 1% (one) had hematologic/
hepatic neonatal lupus. Limiting assessment to the first child 
born during prospective follow-up after a child with NLE 
(to remove possible bias due to multiple pregnancies in the 
same families) showed 36% of pregnancies to be affected 
in total: 23% with NLE and 13% with CHB ± NLE. Sixty-
four percent of pregnancies were unaffected. There were no 
significant differences in maternal risk factors (age, race/
ethnicity, anti-La status, use of steroids, breastfeeding) or in 
fetal sex for having a subsequent child with NLS.64
CHB is a more serious form of NLS, affecting 2% of 
newborns of anti-Ro-positive women with known connective 
tissue diseases65,66 – it remains a very rare condition in the 
general population, affecting 1:20,000 pregnancies.67 If an 
anti-Ro/La-positive woman has had a baby with CHB, then 
the risk to subsequent pregnancies increases to 18%. The 
actual incidence may be higher as incomplete forms of CHB 
have been described, including first-degree heart block that 
can progress during childhood. Most children with CHB will 
need a permanent pacemaker (47%–64% in first year67,68 and 
75% by 10 years),68 and up to 20% may die in the perinatal 
period.66,68 Neonatal CHB may also be the first presentation 
of otherwise asymptomatic connective tissue disease in up to 
50% of women: all mothers of infants with CHB are tested 
for anti-Ro/La antibodies.69
A national review of antenatally diagnosed CHB in 
87 pregnancies over 27 years found no cases detected at 
<18 weeks of gestation. Eighty-two percent were detected 
<30 weeks, with the majority at 20–24 weeks. Subanalysis of 
more recent data (1988–1997) showed that 90% were detected 
<30 weeks. In many cases, this detection followed an initially 
normal fetal heart rate.70 A French registry of 254 CHB cases 
(1976–2014) showed that 94.4% were detected antenatally, 
with a median detection of 23 weeks (range 16–39 weeks).68
Ultrasound assessment of the fetal heart by a fetal medi-
cine or fetal cardiology specialist should thus be performed 
at 18–20 weeks of pregnancy in all women with anti-Ro/La 
antibodies. This enables assessment of atrial and ventricular 
rates, cardiac anatomy and function, and the presence or 
absence of hydrops.69 Many units rescan at 26–28 weeks 
and/or at interim visits.22
The fetal echo provides parental reassurance, but in terms 
of detection of heart block, it is more important for the fetal 
heart rate to be auscultated and recorded every 1–2 weeks 
at an antenatal clinic visit, with urgent referral to a fetal 
medicine unit or fetal cardiology service if a low fetal heart 
rate (<110 bpm) is detected. There is an increased risk of 
hydrops and death if the rate is <55 bpm.71
If evidence of incomplete heart block, myocarditis, asci-
tes, or hydrops is identified, then therapy with fetal steroids 
(dexamethasone or betamethasone) could be considered.22,68 
Three large studies found no benefit on feto-neonatal mortal-
ity;68 one study of historical cases suggested an improvement 
in 1-year survival with steroid treatment.72 Given the potential 
maternal complications with steroid usage, this treatment 
is not routinely recommended.68 Irrespective, the develop-
ment of hydrops in a fetus with CHB is an extremely poor 
prognostic sign, with a mortality rate of 83%–100%.68,72 The 
presence of endocardial fibroelastosis and/or a fetal heart rate 
of <55 bpm are also poor prognostic factors.69
It was previously thought that IVIg might help to reduce 
the rate of recurrent CHB, but two clinical trials have failed to 
show this.73,74 However, a recent case–control study suggested 
a protective effect of HCQ on the development of cardiac 
manifestations in children born to anti-Ro/La-positive moth-
ers. Retrospective data from three large international registers 
were assessed to identify women with anti-Ro/La antibodies 
who had a further pregnancy after a child with CHB. The 
recurrence rate was 7.5% in the group who took HCQ com-
pared with 21.2% in the group who did not.39 Given the good 
safety profile and minimal side effects of HCQ in pregnancy, 
we recommend starting any women with anti-Ro/La-positive 
antibodies on HCQ (400 mg daily) either prepregnancy or 
as soon as possible <16 weeks of gestation, and continuing 
throughout pregnancy.22 They should still receive antenatal 
fetal assessment as outlined earlier.
Antenatal challenge: management 
of pregnancy
All women with SLE who are pregnant should be seen by, 
and have pregnancy care coordinated by, an obstetrician. They 
should also see a rheumatologist familiar with SLE in preg-
nancy at least once. Women should have routine pregnancy 
booking. In addition to booking blood tests (which include a 
FBC), baseline tests of renal and hepatic function, serological 
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status (if unknown), and disease activity (C-reactive protein, 
anti-ds DNA, antibodies, complement) should be obtained. 
Women with previous lupus nephritis, other risk factors for 
poor pregnancy outcome (Table 3), or proteinuria on dipstick 
testing should also have baseline urinary protein quantified 
by PCR or 24-hour collection.8
Women should be seen in the first trimester by both 
obstetrician and rheumatologist to ascertain disease status 
and pregnancy risk. The frequency of subsequent antenatal 
and/or rheumatology clinic visits will depend on these risks, 
plus any factors in the obstetric history and the develop-
ment of any complications in the current pregnancy. As a 
guide, women should be reviewed every 4 weeks from 16 to 
28 weeks, every 2 weeks from 28 to 34 weeks, and every week 
from 34 weeks.8 Each visit should document the presence 
or absence of flare or preeclampsia symptoms, plus blood 
pressure, dipstick urinalysis, symphysial-fundal height, and 
fetal heart rate.
All women with SLE should take low-dose aspirin 
(75 mg) from 12 weeks of pregnancy to reduce their risk of 
preeclampsia.12,25 VTE risk should also be assessed at their 
first visit and throughout pregnancy; those at high risk should 
receive thromboprophylaxis with LMWH and be educated 
about DVT/PE symptoms.18 Antenatal obstetric anesthetic 
review should be arranged for women taking therapeutic or 
high-dose (twice daily) LMWH during pregnancy to discuss 
analgesia options and document an anesthetic plan for labor 
and delivery. Any patients with reduced respiratory func-
tion or cardiorespiratory compromise should also have an 
antenatal obstetric anesthetic review.
Women who have mild, stable disease with no other SLE 
risk factors for a more complicated pregnancy (Table 3) may 
be suitable for ongoing management by obstetricians and 
midwives, with further medical/rheumatological input if 
complications ensue.8
Women with active disease, or those at high risk of compli-
cations, should have regular input from both obstetrician and 
rheumatologist, plus other specialists (eg, nephrologist, cardiol-
ogist) depending on disease manifestations. Ideally, they should 
be managed in a multidisciplinary obstetric– rheumatology 
clinic throughout pregnancy to minimize appointments and 
provide continuity of, and comprehensive, care.
Women with previous hypertension, preeclampsia, and/or 
renal disease should have more frequent blood pressure and 
urinalysis checks than described earlier.8 These additional 
reviews could be with a general practitioner/family  physician, 
or midwife, with referral if any concerns. Proteinuria on 
dipstick analysis would necessitate confirmation and quan-
tification by either PCR or 24-hour collection.
Women on steroids, or those with previous gestational 
diabetes, should have screening for gestational diabetes,8 
ideally at 16 weeks, and if negative, again at 26–28 weeks. 
Depending on local policy, this may be by random blood 
glucose, glycosylated hemoglobin (HbA1c), oral glucose 
tolerance test, or fingerprick blood sugar monitoring.
Women with severe or active SLE should have blood tests 
(as per baseline, described earlier) repeated every 4–8 weeks 
during pregnancy, with interim testing if there are any new-
onset symptoms suggestive of flare or preeclampsia.8
Women should be offered routine pregnancy screening 
and scans, usually a first trimester scan and trisomy screen 
(11–13 weeks) and a fetal anomaly scan (18–22 weeks). Uter-
ine artery Doppler measurements at the latter may be helpful 
to stratify risk: a normal result has a high negative predictive 
value for preeclampsia and IUGR, while an abnormal result 
suggests a higher risk of these conditions.75
Ultrasound scans to assess fetal growth and well-being 
(amniotic fluid assessment, Doppler measurements of fetal 
blood flow) should be performed in patients with active 
disease or previous complex obstetric histories: a standard 
approach might be a late second trimester (26–28 weeks) and 
mid-third trimester (34–36 weeks) scan. If there are particular 
concerns, then scans may be performed every 2–4 weeks, 
with weekly (or more frequent) assessment of amniotic fluid 
and Dopplers, and liaison with a fetal medicine consultant if 
there are signs of fetal compromise. Such scans may also be 
requested for clinical concerns about fetal growth or well-
being (reduced symphysial-fundal height, or reduced fetal 
movements) or in the event of a complication including lupus 
flare or preeclampsia.
Women with anti-Ro/La antibodies should have additional 
monitoring due to the risk of fetal CHB.76 They should be 
referred for fetal echocardiography at 18–20 weeks and again 
at 26–28 weeks. The fetal heart should be auscultated every 
1–2 weeks, with the rate documented. Any fetal heart rate 
abnormality, particularly a slow heart rate, should trigger an 
urgent referral to a tertiary center. Routine antenatal clinic 
appointment frequency can resume after 28 weeks as the 
chance of developing CHB is markedly reduced in the third 
trimester;68 the fetal heart rate should still be documented.
Finally, it should be remembered that 30%–50% of 
pregnancies are unplanned. Women with SLE, therefore, 
may conceive during teratogenic drug therapy. Some patients 
may choose termination of pregnancy; others will wish to 
continue. For the latter, ultrasound confirmation of gestational 
age, and determination of exact exposure dates, is extremely 
important to enable individual risk assessment and accurate 
counseling. Detailed ultrasound scans by fetal medicine 
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experts to screen for major structural abnormalities can be 
undertaken at 12 and 20 weeks of gestation (as per standard 
UK screening), with the option of an “early” anomaly scan 
at 16 weeks. Invasive testing (chorionic villous sampling or 
amniocentesis) is not indicated solely for teratogenic drug 
exposure but would be offered to patients with high-risk 
trisomy screening, or with fetal structural abnormalities.30
Intrapartum challenge: managing 
labor
Women with SLE have an increased risk of preterm delivery. 
This may be spontaneous or may be iatrogenic due to mater-
nal and/or fetal concerns (severe lupus flare, preeclampsia, 
IUGR). A woman in preterm labor with a fetus in a cephalic or 
breech presentation should anticipate a spontaneous vaginal 
delivery, subject to any intrapartum complications; a women 
being delivered preterm for maternal and/or fetal concerns 
may require a cesarean section.
If the fetus is in 24+0–34+6 weeks of gestation, two 
maternal intramuscular steroid injections (betamethasone 
or dexamethasone) should be given to aid fetal lung matura-
tion, ideally >24 hours but <7 days before delivery.77 This is 
independent of any maternal steroids as prednisolone only 
reaches the fetus in minimal quantities (<10% maternal dose) 
due to metabolism by the placenta.33 If the gestational age 
is <32 weeks, there is evidence that magnesium sulfate may 
have fetal neuroprotective benefits (it may also be given to 
women with severe preeclampsia to prevent eclampsia).78
A woman with SLE in spontaneous labor at term with a 
fetus in a cephalic presentation should aim for a spontaneous 
vaginal delivery. Studies have shown that women with SLE 
are more likely to be delivered by cesarean section (>33%, 
OR 1.7): this may be for many reasons, and at a variety of 
gestations.20,21 Cesarean section is an additional risk factor 
for VTE (OR 2–6.7 compared with vaginal birth),18 carries 
risks of bleeding and infection, and has implications for 
future pregnancies. We would thus recommend that Cesarean 
sections should only be performed for obstetric indications 
(maternal and/or fetal concerns).
It may be necessary to adjust maternal medication for 
labor. If a woman is taking long-term oral steroids, she will 
require intravenous hydrocortisone to cover the physiologi-
cal stress of labor and delivery. Ideal regimes are uncertain: 
many practitioners prescribe 50–100 mg intravenous 
 hydrocortisone 8 hourly (eg, 50 mg tds if taking 7.5 to <20 mg 
prednisolone; 100 mg tds if taking ≥20 mg prednisolone).
Women receiving standard prophylactic (once daily) 
doses of LMWH should discontinue it at the onset of 
 spontaneous labor, or the night before induced labor or 
elective cesarean section. They will be able to have regional 
anesthesia (epidural or spinal) 12 hours after the last LMWH 
dose. Women receiving high-dose prophylactic or therapeu-
tic (twice-daily) LMWH should discontinue it at the onset 
of spontaneous labor or 24 hours before induced labor or 
elective cesarean section. They will be able to have regional 
anesthesia 24 hours after the last LMWH dose. Alternative 
analgesia options, such as a patient-controlled analgesia opi-
ate pump, are available for patients requesting additional pain 
relief who are not within a safe post-LMWH time frame for 
regional anesthesia. LMWH can be recommenced 4 hours 
after a spinal injection or after an epidural catheter has been 
removed, provided the woman is hemodynamically stable. 
The epidural catheter should be removed >12 hours after 
the most recent LMWH injection.18
Postpartum challenge: flare, other 
risks, and follow-up
The puerperium (weeks 0–6 postpartum) was thought to be 
a period of high risk of lupus flares,10 although some groups 
have found that disease activity decreases after pregnancy.45 
Of seven prospective comparative studies assessing preg-
nancy and postpartum flares, three showed an increased risk 
of flares; four did not.79 Women taking HCQ, azathioprine, 
and/or steroids for immunosuppression in pregnancy should 
be reassured that these medications are safe for breastfeeding, 
and advised to continue.
If a woman is taking long-term oral steroids, she should 
have received intravenous hydrocortisone to cover the physi-
ological stress of labor and delivery. Postpartum, doubling her 
usual dose of prednisolone for 2–3 days would be considered, 
particularly if she was unwell or had a prolonged labor or com-
plicated delivery, and then her usual dose would be continued.
A member of the multidisciplinary lupus team should 
review the woman on the ward prior to her discharge, with a 
follow-up outpatient appointment for 4–6 weeks postpartum, 
depending on antenatal or intrapartum lupus complications 
and risk factors for lupus complications. This review is to 
detect and manage any postpartum lupus complications, and 
ensure a smooth return to rheumatology outpatient services 
for ongoing care. A thorough history, physical examination, 
blood pressure, and urinalysis should be undertaken, with 
assessment of FBC, U&E, creatinine, LFTs, and disease 
activity markers (erythrocyte sedimentation rate, C-reactive 
protein, anti-dsDNA, and complement).
The woman’s obstetric history should also be considered. 
A recent study of 3,977 parous women with SLE over a 
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38-year period in Sweden showed that those with adverse 
pregnancy outcomes related to maternal–placental syn-
drome (hypertensive disorders of pregnancy, SGA, placental 
abruption, and/or stillbirth) have an increased risk (hazard 
ratio 1.64) and accelerated development of cardiovascular 
events (coronary artery disease, stroke, peripheral vascular 
disease, and/or death from cardiovascular causes) in later 
life when compared with women who had uncomplicated 
pregnancies. The risk was doubled in women with SLE 
and maternal–placental syndrome who delivered a baby at 
<34 weeks of gestation.80
The puerperium is also a period of increased VTE risk. 
All women who received antenatal LMWH should continue 
this for 6 weeks postpartum, in a once-daily dosage (recent 
weight). All women should undergo a postpartum VTE risk 
assessment: many may require a 10-day course for obstetric 
or other reasons (risk factors include age, BMI, parity, aPL, 
cesarean section, postpartum hemorrhage); the threshold for 
postpartum prophylaxis is lower than antenatal as it is a time 
of greater risk.18 Women with previous or recent VTE may 
require long-term anticoagulation: LMWH can be switched 
to warfarin when the risk of hemorrhage has reduced, usually 
at days 5–7 postpartum, with continuation of LMWH until 
the international normalized ratio reaches therapeutic range. 
Some women may be accustomed to LMWH use during 
pregnancy and may prefer to continue postpartum, even for 
an extended course, rather than switching to warfarin with 
its monitoring blood tests.
Postpartum challenge: 
contraception
In addition to rheumatology and/or obstetric medicine 
follow-up appointments, the woman should also attend her 
routine 6-week mother-and-baby check at her general prac-
titioner clinic. This includes clinical review, contraception 
 discussion, cervical smear appointment (if overdue), and 
6-week baby check.
Postpartum counseling and provision of contraception is 
particularly important in patients with SLE (and all patients 
with chronic medical conditions) as planned pregnancy is 
associated with fewer complications and higher pregnancy 
success rates.10
Barrier methods (condom, female condom, diaphragm, 
cap, sponge) are convenient and readily available but have 
a 15%–32% failure rate with typical use. Condoms and 
female condoms also protect against sexually transmitted 
infections.81
Hormonal methods can be divided into those containing 
estrogen and progestogen (combined oral contraceptive pill 
[COCP], contraceptive patch, and contraceptive ring), and 
progestogen-only methods (progestogen-only pill, implant, 
Depo-Provera injection, and Mirena intrauterine system [IUS]).
Estrogen-containing contraceptives increase a woman’s 
VTE risk, so they are contraindicated in women with aPL or 
APS, moderate–severe active SLE (including lupus nephri-
tis), hypertension, smoking, obesity, or previous VTE.82 
Women with well-defined SLE with stable and/or low-active 
disease may be suitable to use the COCP if they wish:82 a 
systematic review of 14 studies, including two randomized 
controlled trials, showed that combined oral contraceptive 
use does not lead to increased disease flares or worsening 
disease activity in women with inactive or stable SLE.83,84
Depo-Provera, progestogen subdermal implants, and 
the IUS are long-acting reversible contraception methods 
which are reliable (failure rate>1%), less reliant on patient 
compliance, and last for up to 3 months, 3 years, and 5 years, 
respectively. The IUS also reduces menstrual blood loss. 
Progestogen-only pills are effective if taken correctly but have 
a narrower compliance window than COCPs. Progestogen-
only methods are safe for women in whom estrogens are 
contraindicated, including those with VTE and hypertension, 
as they do not increase VTE risk. They may cause a small, 
reversible reduction in bone density.81,82,85
The intrauterine contraceptive device, or copper-contain-
ing coil, is also an extremely effective method of contracep-
tion, and does not carry additional VTE risks. It can increase 
menstrual bleeding, so it may not be suitable for women on 
long-term warfarin or LMWH.81,86
Conclusion
Women with SLE, particularly those with associated lupus 
nephritis or APS, are at increased risk of adverse pregnancy 
outcomes. Care should be coordinated by obstetricians, 
midwives, and rheumatologists with expertise in the care of 
high-risk pregnancies. Maintaining disease remission and 
treating any flares rapidly is vital. All clinicians involved in 
the management of SLE pregnancies should feel comfortable 
counseling women regarding medication use in pregnancy 
and in particular advise women not to discontinue antirheu-
matic drugs compatible with pregnancy. Evidence-based 
guidelines from the UK and Europe are now available.
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